Expression of the Decay-Accelerating Factor (CD55) in Renal Transplants—A Possible Prediction Marker of Allograft Survival

Background. Decay-accelerating factor (CD55) accelerates the decay of C3 and C5 convertases, participating in classical and alternative complement activation pathways. Complement activation plays a major role in antibody-mediated rejection of allografts (AMR); C4d is used as a marker of AMR. Emerging evidence suggests an important role of CD55 in the pathogenesis of AMR. The aim of this study was to investigate the expression of CD55 in renal allografts and to correlate it with the expression of C4d, allograft survival, changes in serum creatinine (SC). Methods. More than 200 renal allograft biopsies, performed for allograft dysfunction, were assessed for peritubular capillary (PTC) C4d and CD55 expression. Results. We found significant correlation between changes in SC and PTC CD55 staining pattern in patients with no PTC C4d staining. In these patients, SC increased from baseline by 2.2+0.34, 1.7+0.36, and 0.93+0.24 mg/dL in negative, focal, and diffuse PTC CD55 staining subgroups, respectively. Survival of renal allografts was better in diffuse PTC CD55 staining subgroup than in negative PTC CD55 staining subgroup. Conclusions. These data suggest that CD55 expression has a protective effect on PTC C4d negative renal allografts, and the pattern of PTC CD55 expression may be used as a potential marker of renal allograft survival in patients with no evidence of AMR.

[1]  P. Heeger,et al.  Donor Deficiency of Decay-Accelerating Factor Accelerates Murine T Cell-Mediated Cardiac Allograft Rejection1 , 2008, The Journal of Immunology.

[2]  B. Murtaza,et al.  Paroxysmal nocturnal hemoglobinuria. , 2008, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[3]  R. Ploeg,et al.  Complement and Renal Transplantation: From Donor to Recipient , 2008, Transplantation.

[4]  N. Smedira,et al.  Decay-accelerating factor expression may provide immunoprotection against antibody-mediated cardiac allograft rejection. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[5]  P. Randhawa,et al.  Acute Renal Allograft Rejection: Diagnostic Significance of Focal Peritubular Capillary C4d , 2008, Transplantation.

[6]  R. Pelletier,et al.  Peritubular capillary C4d staining in late acute renal allograft rejection – is it relevant? , 2007, Clinical transplantation.

[7]  N. Sheerin,et al.  Mechanisms of Disease: the complement system in renal injury—new ways of looking at an old foe , 2007, Nature Clinical Practice Nephrology.

[8]  G. Gilkeson,et al.  Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanisms. , 2007, The American journal of pathology.

[9]  R. Colvin.  Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. , 2007, Journal of the American Society of Nephrology : JASN.

[10]  M. Haas,et al.  Antibody-mediated rejection in renal allografts: lessons from pathology. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[11]  M. Sykes,et al.  Decay-Accelerating Factor Prevents Acute Humoral Rejection Induced by Low Levels of Anti-αGal Natural Antibodies , 2006, Transplantation.

[12]  Gang Chen,et al.  The Influence of Baseline Expression of Human Decay Accelerating Factor Transgene on Graft Survival and Acute Humoral Xenograft Rejection , 2005, Transplantation.

[13]  R. Pelletier,et al.  Comparative study for the detection of peritubular capillary C4d deposition in human renal allografts using different methodologies. , 2005, Human pathology.

[14]  M. Mihatsch,et al.  Diagnostic value of C4d in renal biopsies , 2005, Current opinion in nephrology and hypertension.

[15]  J. Thurman,et al.  Acute tubular necrosis is characterized by activation of the alternative pathway of complement. , 2005, Kidney international.

[16]  H. Yang,et al.  Xenotransplantation of human decay accelerating factor transgenic porcine kidney to non-human primates: 4 years experience at a Canadian center. , 2004, Transplantation proceedings.

[17]  M. Nangaku,et al.  Critical Protection from Renal Ischemia Reperfusion Injury by CD55 and CD591 , 2004, The Journal of Immunology.

[18]  R. Colvin,et al.  Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. , 2002, Journal of the American Society of Nephrology : JASN.

[19]  Francis L. Delmonico,et al.  ACUTE HUMORAL REJECTION IN RENAL ALLOGRAFT RECIPIENTS: I. INCIDENCE, SEROLOGY AND CLINICAL CHARACTERISTICS1 , 2001, Transplantation.

[20]  R. Colvin,et al.  Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. , 1999, Journal of the American Society of Nephrology : JASN.

[21]  R. Finberg,et al.  Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. , 1992, Journal of immunology.

[22]  M. L. Le Beau,et al.  The gene encoding decay-accelerating factor (DAF) is located in the complement-regulatory locus on the long arm of chromosome 1 , 1987, The Journal of experimental medicine.

[23]  M. Pangburn,et al.  Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases. , 1986, Journal of immunology.

[24]  V. Nussenzweig,et al.  Decay-accelerating factor is present on cultured human umbilical vein endothelial cells , 1986, The Journal of experimental medicine.

[25]  K. Austen,et al.  Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system. , 1985, Blood.

[26]  E. M. Hoffmann,et al.  Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action. , 1969, Immunochemistry.

[27]  E. M. Hoffmann.  Inhibition of complement by a substance isolated from human erythrocytes — I: Extraction from human erythrocyte stromata , 1969 .

[28]  G. Einecked,et al.  Banff 07 Classification of Renal Allograft Pathology : Updates and Future Directions , 2008 .

[29]  M. Yacoub,et al.  Reduction of hyperacute rejection and protection of metabolism and function in hearts of human decay accelerating factor (hDAF)-expressing pigs. , 2007, Cardiovascular research.